New drug combo aims to help myelofibrosis patients who struggle with current treatments

This study is testing whether adding a new drug called WJ01024 to an existing medication (ruxolitinib) can help people with intermediate- or high-risk myelofibrosis, especially those whose disease hasn't responded well to prior JAK inhibitor treatments. The main goals are to see if the combination is safe and if it can reduce spleen size and ease disease symptoms. The study will enroll about 33 adults who have an enlarged spleen and meet specific health criteria.